STMN1 upregulation mediates HCC and hepatic stellate cells crosstalk to aggravate cancer through triggering MET pathway.
STMN1 has been regarded as an oncogene and its upregulation is closely associated with malignant behaviors and poor prognosis in multiple cancers. However, the detailed functions and underlying mechanisms of STMN1 are still largely unknown in hepatocellular carcinoma (HCC) development. Here, we analyzed STMN1 expression and the related clinical significance in HCC by using well-established Protein Atlas, TCGA and GEO cancer databases. The analysis indicated that STMN1 was highly expressed in HCC and closely associated with vascular invasion, higher histological grade, advanced clinical grade and shorter survival time in HCC patients. Overexpressing and silencing STMN1 in HCC cell lines demonstrated that STMN1 could regulate cell proliferation, migration, drug-resistance, cancer stem cell property in vitro as well as tumor growth in vivo. Further experiments demonstrated that STMN1 mediated intricate crosstalk between HCCs and hepatic stellate cells (HSCs) via triggering the HGF/MET signal pathway. When HSCs were cocultured with HCC cells, HSCs secreted more HGF to stimulate the expression of STMN1 in HCC cells. Mutually, STMN1 upregulation in HCC cells facilitated HSC activation to acquire CAF features. The MET inhibitor crizotinib significantly blocked this crosstalk and slowed tumor growth in vivo. In conclusion, our findings shed new insight on STMN1 functions, and suggest that STMN1 may hopefully be used as a potential marker to identify patients who benefit from MET inhibitor treatment.